A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors

Conclusion.This phase II study met its primary endpoint with an 18‐week DCR of 46%. The clinical activity of dacarbazine plus sorafenib in patients with these diagnoses is modest.Implications for Practice.Metastatic soft tissue sarcomas are a heterogeneous group of relatively rare malignancies. Most patients are treated with cytotoxic chemotherapy or targeted therapy in the form of tyrosine kinase inhibitors. Response rates are relatively low, and there is a need for better therapies. This clinical trial demonstrates that combining a cytotoxic therapy (dacarbazine) with an antiangiogenic small molecule (sorafenib) is feasible and associated with favorable disease‐control rates; however, it also increases the potential for significant toxicity.

Source: The Oncologist - June 17, 2019 Category: Cancer & Oncology Authors: David R. D'Adamo, Mark A. Dickson, Mary L. Keohan, Richard D. Carvaȷal, Martee L. Hensley, Catherine M. Hirst, Marietta O. Ezeoke, Linda Ahn, Li-Xuan Qin, Cristina R. Antonescu, Robert A. Lefkowitz, Robert G. Maki, Gary K. Schwartz, William D. Tap Tags: Sarcomas Source Type: research